Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C

BACKGROUND: Patients with substance use disorders (SUD) and chronic hepatitis C virus infection (HCV) have limited access to direct-acting antivirals (DAAs) due to multilevel issues related to providers (eg, concern about reinfection); patients (eg, refusal); payers (eg, prior authorization); and he...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xinyi, Vouri, Scott Martin, Diaby, Vakaramoko, Lo-Ciganic, Weihsuan, Parker, Robert, Park, Haesuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968723/
https://www.ncbi.nlm.nih.gov/pubmed/34595949
http://dx.doi.org/10.18553/jmcp.2021.27.10.1388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968723/
https://www.ncbi.nlm.nih.gov/pubmed/34595949
http://dx.doi.org/10.18553/jmcp.2021.27.10.1388

Ejemplares similares